CELL METAB 润色咨询

Cell Metabolism

出版年份:2005 年文章数:2031 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:3.5% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2021-10-27 心内一科

    审稿速度:3.0
    偏重的研究方向:临床转化;基础
    经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!

    5

    展开5条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2021-09-07 张晓梅-Xiaomei Zhang

    审稿速度:1.0 | 投稿命中率:5.0
    经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的

    4

    展开4条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2019-04-02 ms8780191241558819

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing!

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2019-04-14 苦逼科研仔

    审稿速度:1.0 | 投稿命中率:5.0
    经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2021-12-28 ms6000000264964247

    一般期刊要求关键词有多少个?

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2021-12-29 Mia

    各个杂志社对关键词的数目有要求么?

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2019-12-03 ms1699298910516592

    审稿速度:1.0
    经验分享:2019.11.29上传
    2019.12.03 scheduled for editorial consideration

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2024-02-11 1224989703 来自重庆

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享:还在pre-accept

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2024-01-26 1224989703 来自广东省

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:免疫;肿瘤;代谢
    经验分享:5.24, 2023 submit

    5.27, 2023 send out for peer review

    7.18, 2023 major revision(invited)

    12.20, 2023 revision submit

    1.25, 2024 Pre-accept

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1064365, encodeId=691c106436589, content=审稿速度:3.0<br>偏重的研究方向:临床转化;基础<br>经验分享:Cell Metabolism是代谢领域的顶刊!但是自从某李姓长江来了之后,画风突变。收新冠的文章也就算了,全球疾病负担(GBD)这种跟代谢没有半毛钱关系的文章都收,只能说李姓长江的关系网不一般啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=518, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Wed Oct 27 14:12:14 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:非常奇怪,近两年武汉大学又连续发了好几篇,有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=652, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850610, encodeId=c4f28506103c, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:18年10月底投,10天送审,12月3号返回意见,邀请大修。19年3月修回,结果未知!祈祷ing! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=625, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Tue Apr 02 21:20:36 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569516, encodeId=45d45695168f, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:18.10.22 submit 18.10.31 send out for peer review 18.12.3 major revision(invited) 19.03.11 revision submit 19.04.06 minor revision 19.04.08 minor revision submit 19.04.10 pre-accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=731, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Sun Apr 14 00:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088493, encodeId=16f4108849383, content=一般期刊要求关键词有多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=554, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088494, encodeId=1a141088494e2, content=各个杂志社对关键词的数目有要求么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=480, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855502, encodeId=fd19855502eb, content=审稿速度:1.0<br>经验分享:2019.11.29上传<br> 2019.12.03 scheduled for editorial consideration , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=565, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb435413957, createdName=ms1699298910516592, createdTime=Tue Dec 03 11:09:56 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;肿瘤;代谢<br>经验分享:5.24, 2023 submit<br><br>5.27, 2023 send out for peer review<br><br>7.18, 2023 major revision(invited)<br><br>12.20, 2023 revision submit<br><br>1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]
    2023-10-24 Zhangbin861109 来自山东省

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:肿瘤
    经验分享:很难接收

    0

共47条页码: 1/5页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分